Factsheet Q3/2012

F FRESENIUS

COMPANY PROFILE

Fresenius is a health care group providing products and services for dialysis, hospitals and the medical care of patients at home. In addition, Fresenius focuses on hospital operation, as well as on engineering and services for hospitals and other health care facilities. More than 163,000 employees have dedicated themselves to the service of health in about 100 countries worldwide.

FRESENIUS GROUP IN FIGURES

€ in millions	Q1-3/2012	2011	2010	2009
Sales and Earnings				
Sales	14,100	16,522	15,972	14,164
EBIT ¹	2,224	2,563	2,418	2,054
Net income ^{2, 5}	682	770	660	514
Earnings per ord. share in € ^{2, 5}	3.98	4.73	4.08	3.18
Balance sheet and cash flow				
Total assets	30,225	26,321	23,577	20,882
Non-current assets	21,604	19,170	17,142	15,519
Equity ³	12,532	10,577	8,844	7,491
Equity ratio ³	42%	40%	38%	36%
Net debt/EBITDA	2.5	2.8	2.6	3.0
Investments ⁴	2,803	2,395	1,402	931
Operating cash flow	1,807	1,689	1,911	1,553
Operating cash flow in % of sales	12.8%	10.2%	12.0%	11.0%
Profitability				
EBIT margin ¹	15.8%	15.5%	15.1%	14.5%
Return on equity after taxes (ROE) ^{5, 7}	11.8%	12.9%	13.3%	12.1%
Return on operating assets (ROOA) ⁶	11.1%	10.9%	11.6%	10.5%
Return on invested capital (ROIC) ⁶	9.1%	8.8%	8.9%	8.2%
Employees (Sept 30/Dec 31)	163,463	149,351	137,552	130,510


¹ 2012: Adjusted for one-time costs related to the offer to the shareholders of RHÖN-KLINIKUM AG. 2 2012: Net income attributable to shareholders of Fresenius SE 6 Co. KGA – adjusted for a non-taxable investment gain at Fresenius Medical Care and for one-time costs related to the offer to the shareholders of RHÖN-KLINIKUM AG.

 ³ Equity including noncontrolling interest
⁴ Investments in property, plant and equipment and intangible assets, acquisitions. Excluding an investment of cash in the amount of €801 million by Fresenius SE & Co. KGaA. ⁵ 2011, 2010 and 2009 adjusted for the effects of the mark-to-market accounting of the MEB and the

CVR ⁶ 2012: The underlying pro forma EBIT does not include one-time costs related to the offer to the

shareholders of RHÖN-KLINIKUM AG. 2012: Adjusted for a non-taxable investment gain at Fresenius Medical Care and for one-time costs related to the offer to the shareholders of RHÖN-KLINIKUM AG.

SALES BY REGION





GROUP STRUCTURE

The operating business comprises the four business segments Fresenius Medical Care, Fresenius Kabi, Fresenius Helios and Fresenius Vamed, all of which are legally independent entities managed by the operating parent company Fresenius SE & Co. KGaA. In addition, with the Fresenius Biotech Fresenius is active in research and development in the field of antibody therapies.


	F FRE	SENIUS	Fresenius Biotech
31% ¹	100%	100%	77%
Fresenius Medical Care	Fresenius Kabi	Fresenius Helios	Fresenius Vamed
¹ as of September 30, 2012			

BUSINESS SEGMENTS

		Q1-3	Q1-3/2012		2011	
€ in m	nillions	Sales	EBIT	Sales	EBIT	
Ţ	FRESENIUS MEDICAL CARE	7,882	1,296	9,192	1,491	
5	FRESENIUS KABI	3,363	700	3,964	803	
1	FRESENIUS HELIOS	2,347	232	2,665	270	
V	FRESENIUS VAMED	536	24	737	44	

- Fresenius Medical Care is the world's leading provider of services and ► products for patients with chronic kidney failure. As of September 30, 2012, Fresenius Medical Care was treating 256,521 patients in 3,135 dialysis clinics.
- Fresenius Kabi offers infusion therapies, intravenously administered generic drugs and clinical nutrition for seriously and chronically ill patients in the hospital and outpatient environments. The company is also a leading supplier of medical devices and transfusion technology products in Germany.
- Fresenius Helios is the largest private hospital operator in Germany. HELIOS owns 72 hospitals, including 6 maximum care hospitals in Berlin-Buch, Duisburg, Erfurt, Krefeld, Schwerin and Wuppertal. HELIOS treats more than 2.7 million patients per year, thereof more than 750,000 inpatients, and operates more than 23,000 beds.
- Fresenius Vamed offers engineering and services for hospitals and other health care facilities.
- Fresenius Biotech develops innovative therapies with trifunctional antibodies for the treatment of cancer.

SALES BY BUSINESS SEGMENT



FRESENIUS SHARE/ADR

	Ordinary share
Securities code no.	578 560
ISIN	DE0005785604
Ticker symbol	FRE
ADR CUSIP	35804M105
ADR Ticker symbol	FSNUY
Number of ordinary shares (September 30, 2012)	177,944,610
Market capitalization (September 30, 2012)	€16.1 billion

FRESENIUS GROUP'S SENIOR NOTES

lssuer	ISIN	Volume in million	Coupon	Matu- rity
Fresenius Finance B.V.	XS0240918218	€500	5.00%	2013
Fresenius Finance B.V.	XS0240919372	€650	5.50%	2016
Fresenius Finance B.V.	XS0759200321	€500	4.25%	2019
Fresenius US Finance II, Inc.	USU31436AD72	US\$500	9.00%	2015
Fresenius US Finance II, Inc.	XS0390398344	€275	8.75%	2015

Bonds of Fresenius Medical Care can be found under www.fmc-ag.com\Credit Relations.

RELATIVE SHARE PRICE PERFORMANCE FRESENIUS SHARE VS. DAX DAX De Fresenius ordinary share

SHARE PERFORMANCE¹

+6.1%


+10.5%

+35.5%


+65.0% +1.143.2%

Targets 2012

Dates



DEVELOPMENT ORDINARY SHARE DIVIDENDS IN €



GROUP OUTLOOK 2012

	· j ·
Sales growth ¹ (in constant currency)	12%-14%
Net income ² , growth (in constant currency)	14%-16%
Capital expenditure	$\sim 5\%$ of group sales

 $^{\rm 1}$ Previous year's sales were adjusted according to a U.S. GAAP accounting change at Fresenius Medical Care.

² Net income attributable to shareholders of Fresenius SE & Co. KGaA - adjusted for a non-taxable investment gain (€34 million) and potential special charges (up to €17 million) at Fresenius Medical Care as well as for one-time costs (€31 million) related to the offer to the shareholders of RHÖN-KLINIKUM AG.

For the outlook of the business segments please see the Investor News of October 31, 2012.

FINANCIAL CALENDAR

Report on Fiscal Year 2012	February 26, 2013
Report on 1 st quarter 2013	April 30, 2013
Annual General Meeting, Frankfurt/Main	May 17, 2013
Report on 1 st half 2013	July 30, 2013
Report on 1 st -3 rd quarter 2013	November 5, 2013

This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius does not undertake any respon-sibility to update the forward-looking statements in this release.

Fresenius SE & Co. KGaA

Registered Office: Bad Homburg, Germany Commercial Register: Amtsgericht Bad Homburg, HRB 11852 Chairman of the Supervisory Board: Dr. Gerd Krick

General Partner: Fresenius Management SE Registered Office: Bad Homburg, Germany

Commercial Register: Amtsgericht Bad Homburg, HRB 11673 Management Board: Dr. Ulf M. Schneider (Chairman), Rainer Baule, Dr. Francesco De Meo, Dr. Jürgen Götz, Dr. Ben Lipps, Stephan Sturm, Dr. Ernst Wastler Chairman of the Supervisory Board: Dr. Gerd Krick

CONTACT

Fresenius SE & Co. KGaA Birgit Grund Senior Vice President Investor Relations Else-Kröner-Straße 1

61352 Bad Homburg v. d. H.

Telephone: ++49 61 72 6 08-24 85 Telefax: ++49 61 72 6 08-24 88 e-mail: ir-fre@fresenius.com Internet: www.fresenius.de